Celadon Pharmaceuticals to Cancel AIM Listing and Re-register as Private Company

Celadon Pharmaceuticals PLC ( (GB:CEL) ) has shared an update.

Celadon Pharmaceuticals announced that all resolutions at its recent general meeting were passed, leading to the cancellation of its AIM listing and re-registration as a private company. The company’s shares are currently suspended due to delayed financial reporting, and a matched bargain facility will be provided for shareholders to trade shares post-cancellation. This strategic shift may impact the company’s market presence and shareholder engagement, as it transitions away from public trading.

More about Celadon Pharmaceuticals PLC

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions like autism. Its EU-GMP approved facility in the UK includes indoor hydroponic cultivation, GMP extraction, and an R&D laboratory. Celadon holds a Home Office license for the commercial supply of pharmaceutical-grade cannabis and owns a clinical trial for treating chronic pain with cannabis-based products. The company also has a minority interest in Kingdom Therapeutics, which is developing a cannabinoid medicine for Autism Spectrum Disorder.

Average Trading Volume: 85,717

Technical Sentiment Signal: Sell

Current Market Cap: £9.23M

Learn more about CEL stock on TipRanks’ Stock Analysis page.